# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Mayfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening. **S**

## Historical basis

- Billie Holiday was born Eleanora Fagan in Philadelphia on April 7, 1915, and was raised in Baltimore by her mother, Sarah Julia "Sadie" Fagan. **D**
- Her mother died in October 1945; afterwards Holiday drank more heavily and her drug use increased as she grieved. **D**
- Holiday began using heroin in the early 1940s, and her addiction became severe in the late 1940s; she was arrested repeatedly over her heroin use in that period. **D**
- In May 1947 Holiday was arrested for narcotics possession; she pleaded guilty, was sentenced to a year and a day, and was held at the federal facility for women at Alderson, West Virginia, until her early release on March 16, 1948. **D**
- Holiday sought treatment for her addiction, at one point checking herself into an institution in the hope of breaking her habit. **D**
- Her conviction cost her the New York City cabaret card she needed to perform in clubs that served alcohol. **D**
- The Federal Bureau of Narcotics pursued Holiday for years, and later writers have described that pursuit as driven by racism and linked it to her performance of "Strange Fruit," a song against lynching. **R**

3 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- She wants to stay off heroin and keep singing, and is afraid of losing her tolerance and overdosing. **S**
- She wants to drink less, especially around shows. **S**
- She wants her records kept private and to be treated without judgment. **S**

## Strengths and supports

- Supports: musicians she has worked with for years, a close friend who has agreed to carry naloxone, and a peer recovery coach; her music is her strongest source of purpose **S**

## Medications and allergies

- Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 **S**
- Thiamine 100 mg oral tablet, one tablet by mouth daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- about 1943: Heroin use from the early 1940s, becoming a severe addiction in the late 1940s; sought treatment for it at least once **D** (CLM-0003, CLM-0005)
- October 1945: Heavier drinking and increased drug use after her mother's death **D** (CLM-0002)
- March 16, 1948: Federal custody after a narcotics possession conviction, about ten months with enforced abstinence; released early **D** (CLM-0004)

## Procedures and immunizations

- No procedures before this visit. **S**
- 1948-04-20: Tdap vaccine **S**
- 1948-04-20: Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**
- 1948-04-20: Hepatitis A vaccine, adult, dose 1 of 2 **S**
- 1948-04-20: Pneumococcal conjugate vaccine PCV20 **S**

## Family history

- mother: Died in 1945; cause not recorded in the cited source **D** (CLM-0002)

## Measurements

Hemoglobin: 12.4 g/dL; MCV: 101 fL (high); Platelets: 236 10*3/uL; Sodium: 138 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.72 mg/dL; eGFR: 113 mL/min/1.73 m²; Glucose: 88 mg/dL; AST: 52 U/L (high); ALT: 38 U/L; GGT: 84 U/L (high); Albumin: 4 g/dL; Total bilirubin: 0.7 mg/dL; Hepatitis C antibody (signal-to-cutoff): 0.09; Hepatitis B surface antibody: 3 m[IU]/mL (low); Phosphatidylethanol (PEth): 312 ng/mL (high); PHQ-9: 9; AUDIT-C: 8; DAST-10: 7. All results are synthetic.

BP 126/80 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 68 kg; BMI 25 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, guarded at first and then candid; speech normal; no signs of intoxication or withdrawal; Mood low and tired, with grief for her mother that still returns; PHQ-9 score 9 with item 9 scored 0; no thoughts of suicide or self-harm. Functional status: Independent in all activities; performing several nights a week; sleep broken since release. Physical examination is intentionally limited. **S**

## Safety assessment

Current ideation: absent; intent: absent; plan: absent; access reviewed: yes. Disposition: Outpatient care. Overdose risk is high in the weeks after release because tolerance has fallen: naloxone for her and her friend, never using alone, testing any drug supply with fentanyl test strips, and buprenorphine started today. The 988 Suicide & Crisis Lifeline was given and saved in her phone, and a written safety plan was made with her. Safety reviewed at every visit. This is synthetic and does not convert historical behavior into a current finding. **S**

## Assessment

1. Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use; status draft. **S**
2. Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death; status draft. **S**

## Plan

- Buprenorphine with naloxone started in primary care at a low first dose, then 16 mg daily, continued through any return to use; naloxone, overdose education, never using alone, and fentanyl test strips. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Addiction medicine consultation to confirm the medication plan, choose a medicine for alcohol use disorder that can be used with buprenorphine, and set the monitoring plan. Guideline: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021) **S**
- Liver and infection screening: liver tests and FIB-4 at intake and six months, hepatitis C antibody, hepatitis B triple panel, and HIV test, with hepatitis A and B vaccines for a person who is not immune. Guideline: Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020); Human Immunodeficiency Virus (HIV) Infection: Screening (2019) **S**
- Depression screening with the PHQ-9 at each recovery visit, a structured safety assessment with a written safety plan and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020), U.S. Preventive Services Task Force
- Human Immunodeficiency Virus (HIV) Infection: Screening (2019), U.S. Preventive Services Task Force
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
